Neurocrine biosciences reports first quarter 2024 financial results

Ingrezza® (valbenazine) first quarter net product sales of $506 million representing 23% year-over-year growth ingrezza® sprinkle (valbenazine) capsules approved by the u.s. fda crinecerfont new drug applications for the treatment of congenital adrenal hyperplasia submitted to the u.s. fda positive phase 2 top-line data for nbi-1065845, a potential first-in-class ampa positive allosteric modulator, in adults with major depressive disorder san diego , may 1, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the first quarter ended march 31, 2024 and provided an update on its 2024 financial guidance. "significant unmet need still exists for the many patients living with tardive dyskinesia as exemplified with ingrezza's first quarter year-over-year growth of 23%," said kevin gorman, ph.d.
NBIX Ratings Summary
NBIX Quant Ranking